Acadia Pharmaceuticals Inc. ACAD
21.23 USD -0.01 (-0.05%)
At closeNov 6, 2026, 4:50 PM EST
21.23 0.00 0.00%
After hours · Nov 6, 4:50 PM ET
20.59 Day range 21.44
18.62 52-week range 30.57
- YTD
- -20.52%
- 1 year
- -1.94%
News
benzinga.com Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38 Canaccord Genuity analyst Sumant Kulkarni maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to $38.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.
benzinga.com RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38 RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $38.
seekingalpha.com Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
zacks.com Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.26 per share a year ago.
marketbeat.com What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call ACADIA Pharmaceuticals NASDAQ: ACAD reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and…
benzinga.com ACADIA Pharmaceuticals Q3 2026 Earnings Call Transcript ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com ACADIA Pharmaceuticals Narrows FY2026 Sales Guidance from $1.240B-$1.300B to $1.265B-$1.295B vs $1.272B Est ACADIA Pharmaceuticals (NASDAQ:ACAD) narrows FY2026 sales outlook from $1.240 billion-$1.300 billion to $1.265 billion-$1.295 billion vs $1.272 billion estimate.
businesswire.com Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter,…
benzinga.com Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target Needham analyst Ami Fadia reiterates Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $35 price target.- benzinga.com UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23 UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
benzinga.com RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36 RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.
benzinga.com Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.” https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-allowance-of-u-s--patent-covering-weight-banded-dosing-of-trofinetide-extending-u-s--patent-protections-to-march-2041
benzinga.com Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31 Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.- benzinga.com HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33 HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.
benzinga.com AMD To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings remained unchanged.- benzinga.com Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33 Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.
- benzinga.com BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34 BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.
- benzinga.com Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35 Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.
- benzinga.com Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33 Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.
benzinga.com Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer’s psychosis and plans to move into Phase 3.
benzinga.com Crude Oil Rises Over 4%; Darden Earnings Miss Views U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
benzinga.com Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $41 price target.
benzinga.com Acadia’s Remlifanserin Advances Toward Phase 3 In Alzheimer’s Psychosis Despite Narrow Miss On Primary Endpoint -- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect--…
benzinga.com Acadia Pharmaceuticals Receives Preliminary Court Approval Of Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action On August 24, 2026, the United States District Court for the Southern District of California (the "Court") preliminarily approved the settlement ("Settlement") of the stockholder derivative action- benzinga.com Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38 Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.
- benzinga.com Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28 Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.
- benzinga.com Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40 Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.
- benzinga.com UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49 UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $45 to $49.
- benzinga.com Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41 Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.
- benzinga.com Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39 Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $39.
- benzinga.com Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25 Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $23 to $25.
- benzinga.com RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37 RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $37.
- benzinga.com Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36 Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises the price target from $35 to $36.
- benzinga.com ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.
- benzinga.com ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.07 by 157.14 percent. This is a 12.5 percent increase over earnings…
- benzinga.com BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36 BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $34 to $36.
benzinga.com Robinhood To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts change outlook on top names. See all rating changes, including upgrades and downgrades, on analyst ratings page.- benzinga.com Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25 Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises the price target from $24 to $25.
- benzinga.com Acadia Pharma Secures FDA Fast Track Designation For Remlifanserin For Treatment Of Hallucinations And Delusions Associated With Alzheimer’s Disease Psychosis -- Designation underscores the significant unmet need for new treatment options for Alzheimer’s disease psychosis, a serious condition with no FDA-approved therapies-- RADIANT Phase 2 enrollment…
- benzinga.com RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36 RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $29 to $36.
- benzinga.com B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30 B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $29 to $30.
- benzinga.com Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $35 Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $32 to $35.
- benzinga.com Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36 Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $32 to $36.
benzinga.com Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy Acadia shares rise after CHMP recommends DAYBU for Rett syndrome in the European Union, reversing an earlier negative opinion.
benzinga.com Crude Oil Falls 4%; US Consumer Sentiment Rises In June U.S. stocks slightly up, Dow Jones gains 0.1%. Health care shares jump 2.8%, ON Semiconductor down 20%. Oil down 4%, gold up 1.2%, eurozone and Asian markets closed lower.
benzinga.com Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-market session. The company's market cap stands at $33.0 million. INVO Fertility (NASDAQ:IVF) shares…- benzinga.com Acadia Pharmaceuticals Gets EMA CHMP Positive Opinion Recommending DAYBU Marketing Authorization For Rett Syndrome -- European Commission decision expected in the coming months-- If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European UnionAcadia…
- benzinga.com Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32 Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $33 to $32.